Something in the air: hyperoxic conditioning of the tumor microenvironment for enhanced immunotherapy

Cancer Cell. 2015 Apr 13;27(4):435-6. doi: 10.1016/j.ccell.2015.03.014.


Recent clinical trials in cancer therapy have demonstrated unprecedented responses through blockade of CTLA-4 and PD-1 immune checkpoint pathways. In a provocative recent paper in Science Translational Medicine, Hatfield and colleagues demonstrate the ability of supplemental oxygen to act as a novel immune checkpoint inhibitor by disrupting the hypoxia-adenosine-A2aR pathway.

Publication types

  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / immunology*
  • Oxygen / therapeutic use*


  • Antineoplastic Agents
  • Oxygen